Sterilizes medical devices at fixed facilities that manufacturers are legally locked into by FDA rules.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is above the global median
Sterilizes medical devices at fixed facilities that manufacturers are legally locked into by FDA rules.
Steris plc sterilizes medical devices — using either gamma radiation or ethylene oxide gas — at a network of fixed facilities, and because the FDA requires each sterilization cycle to be validated at the exact building where it runs, every manufacturer's regulatory paperwork names a specific Steris address. Moving to a different sterilization plant requires filing amendments with regulators and completing a six-to-twelve-month requalification study before a single unit can legally ship from the new site, which means manufacturers are effectively locked in from the moment their first product is validated. Building a competing network cannot be solved with money alone: each new facility needs Nuclear Regulatory Commission licensing for cobalt-60 sources, community permits for ethylene oxide operations, and years of approvals before a single device owner can even begin their own validation studies. The arrangement holds only as long as the chambers stay open — if the EPA tightens ethylene oxide emission thresholds enough to force closures, manufacturers whose devices cannot tolerate gamma radiation would have no revalidated alternative to move to, and the coverage that makes the lock valuable would disappear with the capacity.
How does this company make money?
The company charges a fee for each sterilization cycle it runs, with the price based on how much product fills the chamber and which method — ethylene oxide or gamma radiation — is used. It also earns money by running the validation testing studies that device manufacturers must complete before their products can be approved for a given facility, and by helping manufacturers develop sterilization cycles for entirely new devices.
What makes this company hard to replace?
Switching sterilization providers requires a 6-to-12-month revalidation study at the new facility before a single unit can legally ship from there. On top of that, every manufacturer's quality management system registration names the current sterilization facility by address, so moving requires formal regulatory filing amendments. In some regions, fragile devices that cannot travel long distances face even fewer alternative facilities nearby, shrinking the options further.
What limits this company?
Adding more ethylene oxide capacity is not as simple as buying new equipment. EPA Clean Air Act rules require emission control systems that cannot be bolted onto existing chambers — the whole facility has to be rebuilt from scratch. That means throughput can only grow when an entirely new facility is constructed, which takes years.
What does this company depend on?
The company cannot run without ethylene oxide gas for sterilization cycles, cobalt-60 radioactive sources that come from Canadian nuclear reactors, FDA approval of sterilization cycle parameters at each facility, Good Manufacturing Practice certifications that keep those facilities legally operational, and specialized transport containers for moving radioactive materials.
Who depends on this company?
Single-use medical device manufacturers that have no in-house sterilization capability would face months of regulatory requalification work if this company's capacity disappeared. Pharmaceutical companies making sterile injectable products would experience production halts. Hospital systems would run short of sterile surgical instruments and implants.
How does this company scale?
Within an existing facility, the company can handle more volume by packing sterilization loads more efficiently and scheduling cycles more tightly — both of which cost very little. What does not scale cheaply is geographic reach: opening a new facility requires years of regulatory approvals, Nuclear Regulatory Commission licensing for cobalt-60, and community acceptance for ethylene oxide operations.
What external forces can significantly affect this company?
The EPA can force facility modifications or outright closures by tightening ethylene oxide emission standards under the Clean Air Act. The Nuclear Regulatory Commission sets the rules for how cobalt-60 sources are handled and secured. And because cobalt-60 comes from Canadian nuclear reactors, any disruption to that supply chain — whether from reactor maintenance, export policy, or geopolitical friction — would affect the company's ability to run gamma sterilization.
Where is this company structurally vulnerable?
If the EPA tightens ethylene oxide emission limits under the Clean Air Act to the point where existing chambers must close, the network loses the geographic coverage that makes its lock valuable. Device manufacturers whose products cannot tolerate gamma radiation — meaning ethylene oxide is their only option — would have nowhere validated to go, but the company would also have lost the capacity that made it indispensable in the first place.
Sign in to view price data.
Sign inScreen for dividend patterns
Find other stocks with similar dividend characteristics in the screener.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph